HomePipelineOverview
Program | Indication | Early discovery |
Late discovery |
Pre-clinical | Phase I | Phase II / III | ||
---|---|---|---|---|---|---|---|---|
Angiogenesis | ABL001 (Anti-VEGF/DLL4 BsAb) |
Solid cancer |
||||||
Dual VEGF/DLL4 Inhibition Overcomes VEGF Therapy Resistance Dual Blockade of VEGF & DLL4 overcomes VEGF resistance
ABL001 is BETTER than Avastin |
||||||||
Immuno-Oncology | Grabody™ T Platform (Multiple Pipelines) ABL10X |
Cancer | ||||||
Grabody™ T/I Platform ABL50X |
Cancer | |||||||
I/O mAb ABL40X |
Cancer | |||||||
Antibody-Drug Conjugate (ADC) |
ABL20X | Cancer | ||||||
Brief Summary of ADC Pipeline Site-specific ADC (LegoChem Collaboration) ABL202: ADC for Solid Cancer and Leukemia ABL203: ADC for Solid Cancer |
||||||||
Neurology | Grabody™ B (BBB Shuttle) (ɑ-Synuclein / BBB: ABL301) |
Parkinson’s Disease |
||||||